The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
219
Administered orally
Administered orally
Administered IV
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States
Clinical Pharmacology of Miami
Miami, Florida, United States
Fortrea Clinical Research Unit
Dallas, Texas, United States
Endeavor Clinical Trials
San Antonio, Texas, United States
Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline up to Week 9
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4086940
Time frame: Predose up to Day 64
PK: Area Under the Concentration Versus Time Curve (AUC) of LY4086940
Time frame: Predose up to Day 64
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.